The natural history of progressive fibrosing interstitial lung diseases
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
We used data from the INBUILD and INPULSIS trials to investigate the natural history of progressive fibrosing interstitial lung diseases (ILDs). Subjects in the two INPULSIS trials had a clinical diagnosis of idiopathic pulmonary fibrosis (IPF) while subjects in the INBUILD trial had a progressive fibrosing ILD other than IPF and met protocol-defined criteria for ILD progression despite management. Using data from the placebo groups, we compared the rate of decline in forced vital capacity (FVC) (mL·year −1 ) and mortality over 52 weeks in the INBUILD trial with pooled data from the INPULSIS trials. The adjusted mean annual rate of decline in FVC in the INBUILD trial (n=331) was similar to that observed in the INPULSIS trials (n=423) (−192.9 mL·year −1 and −221.0 mL·year −1 , respectively; nominal p-value=0.19). The proportion of subjects who had a relative decline in FVC >10% predicted at Week 52 was 48.9% in the INBUILD trial and 48.7% in the INPULSIS trials, and the proportion who died over 52 weeks was 5.1% in the INBUILD trial and 7.8% in the INPULSIS trials. A relative decline in FVC >10% predicted was associated with an increased risk of death in the INBUILD trial (hazard ratio 3.64) and the INPULSIS trials (hazard ratio 3.95). These findings indicate that patients with fibrosing ILDs other than IPF, who are progressing despite management, have a subsequent clinical course similar to patients with untreated IPF, with a high risk of further ILD progression and early mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At this point, no biomarker or clinical prediction algorithm has been established as a reliable predictor for disease outcome or response to therapy in ILD.(233)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [233]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationTravis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Self-citationDiagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationNintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005 · cited 1×
“Nintedanib is an intracellular inhibitor of tyrosine kinases [10, 25].”
BackgroundMechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 1×
“Along with these clinical similarities, progressive fibrosing ILDs appear to share pathobiological mechanisms that may represent a common fibrotic response to tissue injury [6-10].”
BackgroundSelf-citationUsual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
Kim, E. J., Elicker, B. M., Maldonado, F., Webb, W. R., Ryu, J. H., Van Uden, J. H., Lee, J. S., King, T. E., & Collard, H. R. (2010) · European Respiratory Journal · doi:10.1183/09031936.00092309 · Cited by 587 · cited 2×
“Previous studies have suggested that in patients with fibrosing ILDs, the presence of a UIP-like fibrotic pattern on HRCT is associated with more rapid disease progression [11, 29-32].”
BackgroundWells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30036-9 · Cited by 569
Self-citationdu Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., King, T. E., Lancaster, L., Noble, P. W., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201105-0840oc · Cited by 527 · cited 1×
“Declines in FVC of >10% and >5% predicted have been associated with mortality in patients with IPF [33, 34] and other chronic fibrosing ILDs [19-22].”
BackgroundSelf-citationPredictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Solomon, J. J., Chung, J. H., Cosgrove, G. P., Demoruelle, M. K., Fernandez-Perez, E. R., Fischer, A., Frankel, S. K., Hobbs, S. B., Huie, T. J., Ketzer, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00357-2015 · Cited by 388 · cited 2×
“Declines in FVC of >10% and >5% predicted have been associated with mortality in patients with IPF [33, 34] and other chronic fibrosing ILDs [19-22].”
BackgroundSelf-citationGoh, N. S., Hoyles, R. K., Denton, C. P., Hansell, D. M., Renzoni, E. A., Maher, T. M., Nicholson, A. G., & Wells, A. U. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40130 · Cited by 354 · cited 2×
“Declines in FVC of >10% and >5% predicted have been associated with mortality in patients with IPF [33, 34] and other chronic fibrosing ILDs [19-22].”
BackgroundSelf-citationWhat's in a name? That which we call IPF, by any other name would act the same
Wells, A. U., Brown, K. K., Flaherty, K. R., Kolb, M., & Thannickal, V. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.00692-2018 · Cited by 352 · cited 3×
“In addition to IPF, there are a number of other ILDs that may develop a progressive fibrosing phenotype characterised by declining lung function, an increasing extent of fibrosis on high resolution computed tomography (HRCT), worsening symptoms and quality of life, and early mortality [2-5].”
BackgroundResultSelf-citationFibrosing interstitial lung diseases: knowns and unknowns
Cottin, V., Wollin, L., Fischer, A., Quaresma, M., Stowasser, S., & Harari, S. (2019) · European Respiratory Review · doi:10.1183/16000617.0100-2018 · Cited by 336 · cited 1×
“In addition to IPF, there are a number of other ILDs that may develop a progressive fibrosing phenotype characterised by declining lung function, an increasing extent of fibrosis on high resolution computed tomography (HRCT), worsening symptoms and quality of life, and early mortality [2-5].”
BackgroundSelf-citationPhysiology Is a Stronger Predictor of Survival than Pathology in Fibrotic Interstitial Pneumonia
Jegal, Y., Kim, D. S., Shim, T. S., Lim, C.-M., Do Lee, S., Koh, Y., Kim, W. S., Kim, W. D., Lee, J. S., Travis, W. D., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200403-331oc · Cited by 308 · cited 1×
“Similar to IPF, a decline in forced vital capacity (FVC) is predictive of mortality in patients with these other fibrosing ILDs [18-22].”
BackgroundPotential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
Wollin, L., Distler, J. H. W., Redente, E. F., Riches, D. W. H., Stowasser, S., Schlenker-Herceg, R., Maher, T. M., & Kolb, M. (2019) · European Respiratory Journal · doi:10.1183/13993003.00161-2019 · Cited by 296 · cited 2×
“Along with these clinical similarities, progressive fibrosing ILDs appear to share pathobiological mechanisms that may represent a common fibrotic response to tissue injury [6-10].”
BackgroundSelf-citationCellular interactions in the pathogenesis of interstitial lung diseases
Bagnato, G., & Harari, S. (2015) · European Respiratory Review · doi:10.1183/09059180.00003214 · Cited by 277 · cited 1×
“Along with these clinical similarities, progressive fibrosing ILDs appear to share pathobiological mechanisms that may represent a common fibrotic response to tissue injury [6-10].”
BackgroundThe natural history of progressive fibrosing interstitial lung diseases
Kolb, M., & Vašáková, M. (2019) · Respiratory Research · doi:10.1186/s12931-019-1022-1 · Cited by 269 · cited 1×
“In addition to IPF, there are a number of other ILDs that may develop a progressive fibrosing phenotype characterised by declining lung function, an increasing extent of fibrosis on high resolution computed tomography (HRCT), worsening symptoms and quality of life, and early mortality [2-5].”
BackgroundAn integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study
Walsh, S. L., Wells, A. U., Sverzellati, N., Keir, G. J., Calandriello, L., Antoniou, K. M., Copley, S. J., Devaraj, A., Maher, T. M., Renzoni, E., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70276-5 · Cited by 232 · cited 1×
“The ILDs that can be complicated by progressive fibrosis include idiopathic non-specific interstitial pneumonia (iNSIP) [11], unclassifiable idiopathic interstitial pneumonia (IIP) [12], hypersensitivity pneumonitis (HP) [13], autoimmune ILDs such as rheumatoid arthritisassociated ILD [14] and systemic sclerosis-assoc…”
BackgroundSelf-citationWalsh, S. L. F., Sverzellati, N., Devaraj, A., Keir, G. J., Wells, A. U., & Hansell, D. M. (2014) · Thorax · doi:10.1136/thoraxjnl-2013-203843 · Cited by 229 · cited 1×
“Previous studies have suggested that in patients with fibrosing ILDs, the presence of a UIP-like fibrotic pattern on HRCT is associated with more rapid disease progression [11, 29-32].”
Self-citationPrasse, A., Pechkovsky, D. V., Toews, G. B., Schäfer, M., Eggeling, S., Ludwig, C., Germann, M., Kollert, F., Zissel, G., & Müller‐Quernheim, J. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22559 · Cited by 227 · cited 1×
“Along with these clinical similarities, progressive fibrosing ILDs appear to share pathobiological mechanisms that may represent a common fibrotic response to tissue injury [6-10].”
BackgroundSelf-citationProgressive Decline of Lung Function in Rheumatoid Arthritis–Associated Interstitial Lung Disease
Zamora‐Legoff, J. A., Krause, M. L., Crowson, C. S., Ryu, J. H., & Matteson, E. L. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39971 · Cited by 215 · cited 1×
“Previous studies have suggested that in patients with fibrosing ILDs, the presence of a UIP-like fibrotic pattern on HRCT is associated with more rapid disease progression [11, 29-32].”
Salisbury, M. L., Gu, T., Murray, S., Gross, B. H., Chughtai, A., Sayyouh, M., Kazerooni, E. A., Myers, J. L., Lagstein, A., Konopka, K. E., et al. (2019) · Chest · doi:10.1016/j.chest.2018.08.1076 · Cited by 213 · cited 1×
“Previous studies have suggested that in patients with fibrosing ILDs, the presence of a UIP-like fibrotic pattern on HRCT is associated with more rapid disease progression [11, 29-32].”
Volkmann, E. R., Tashkin, D. P., Sim, M., Li, N., Goldmuntz, E., Keyes-Elstein, L., Pinckney, A., Furst, D. E., Clements, P. J., Khanna, D., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213708 · Cited by 197
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
Richeldi, L., Ryerson, C. J., Lee, J. S., Wolters, P. J., Koth, L. L., Ley, B., Elicker, B. M., Jones, K. D., King, T. E., Ryu, J. H., et al. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-201184 · Cited by 185 · cited 1×
“Declines in FVC of >10% and >5% predicted have been associated with mortality in patients with IPF [33, 34] and other chronic fibrosing ILDs [19-22].”
BackgroundChange in FVC and survival in chronic fibrotic hypersensitivity pneumonitis
Gimenez, A., Storrer, K., Kuranishi, L., Soares, M. R., Ferreira, R. G., & Pereira, C. A. C. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-210035 · Cited by 184 · cited 2×
“Declines in FVC of >10% and >5% predicted have been associated with mortality in patients with IPF [33, 34] and other chronic fibrosing ILDs [19-22].”
BackgroundFlaherty, K. R., Brown, K. K., Wells, A. U., Clerisme-Beaty, E., Collard, H. R., Cottin, V., Devaraj, A., Inoue, Y., Le Maulf, F., Richeldi, L., et al. (2017) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2017-000212 · Cited by 184 · cited 1×
“Given their clinical and pathophysiological similarities, and the rarity of the individual diseases, it has been proposed that fibrosing ILDs with a progressive phenotype be “lumped” together for the purposes of investigating certain potential therapies [3, 23, 24].”
BackgroundSelf-citationDe Sadeleer, L. J., Hermans, F., De Dycker, E., Yserbyt, J., Verschakelen, J. A., Verbeken, E. K., Verleden, G. M., & Wuyts, W. A. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm8010014 · Cited by 173
Adegunsoye, A., Oldham, J. M., Bellam, S. K., Montner, S., Churpek, M. M., Noth, I., Vij, R., Strek, M. E., & Chung, J. H. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201807-443oc · Cited by 161 · cited 1×
“Previous studies have suggested that in patients with fibrosing ILDs, the presence of a UIP-like fibrotic pattern on HRCT is associated with more rapid disease progression [11, 29-32].”
Lung Manifestations in the Rheumatic Diseases
Doyle, T. J., & Dellaripa, P. F. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.05.015 · Cited by 133 · cited 1×
“The ILDs that can be complicated by progressive fibrosis include idiopathic non-specific interstitial pneumonia (iNSIP) [11], unclassifiable idiopathic interstitial pneumonia (IIP) [12], hypersensitivity pneumonitis (HP) [13], autoimmune ILDs such as rheumatoid arthritisassociated ILD [14] and systemic sclerosis-assoc…”
BackgroundHeterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis
Guler, S. A., Ellison, K., Algamdi, M., Collard, H. R., & Ryerson, C. J. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201801-067oc · Cited by 121 · cited 4×
“To assess whether specific ILD diagnoses were associated with different rates of progression, the course of ILD in the placebo group of the INBUILD trial was assessed in the following five diagnostic groups: iNSIP, unclassifiable IIP, HP, autoimmune ILDs (RA-ILD, SSc-ILD, MCTD-ILD, plus subjects with an autoimmune dis…”
BackgroundInfluentialGuler, S. A., Winstone, T. A., Murphy, D. T., Hague, C. J., Soon, J., Sulaiman, N., Li, K. H., Dunne, J. V., Wilcox, P., & Ryerson, C. J. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201806-362oc · Cited by 111 · cited 1×
“The ILDs that can be complicated by progressive fibrosis include idiopathic non-specific interstitial pneumonia (iNSIP) [11], unclassifiable idiopathic interstitial pneumonia (IIP) [12], hypersensitivity pneumonitis (HP) [13], autoimmune ILDs such as rheumatoid arthritisassociated ILD [14] and systemic sclerosis-assoc…”
BackgroundEnvironmental, Inhaled and Ingested Causes of Pulmonary Fibrosis
Khalil, N., Churg, A., Müller, N. L., & O'Connor, R. N. (2007) · Toxicologic Pathology · doi:10.1080/01926230601064787 · Cited by 56 · cited 1×
“The ILDs that can be complicated by progressive fibrosis include idiopathic non-specific interstitial pneumonia (iNSIP) [11], unclassifiable idiopathic interstitial pneumonia (IIP) [12], hypersensitivity pneumonitis (HP) [13], autoimmune ILDs such as rheumatoid arthritisassociated ILD [14] and systemic sclerosis-assoc…”
BackgroundSystemic sclerosis-associated fibrosis: an accelerated aging phenotype?
Luckhardt, T., & Thannickal, V. J. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000219 · Cited by 39 · cited 1×
“Along with these clinical similarities, progressive fibrosing ILDs appear to share pathobiological mechanisms that may represent a common fibrotic response to tissue injury [6-10].”
BackgroundSelf-citationTorrisi, S. E., Kahn, N. C., Wälscher, J., Sarmand, N., Polke, M., Kehler, L., Eichinger, M., Heußel, C. P., Palmucci, S., Sambataro, F. M., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0937-0 · Cited by 35 · cited 1×
“Given their clinical and pathophysiological similarities, and the rarity of the individual diseases, it has been proposed that fibrosing ILDs with a progressive phenotype be “lumped” together for the purposes of investigating certain potential therapies [3, 23, 24].”
BackgroundKim, M. Y., Song, J. W., Do, K., Jang, S. J., Colby, T. V., & Kim, D. S. (2012) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0b013e31823ed437 · Cited by 19
Cited by
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
“Therefore, the committee derived the physiological criteria for PPF by extrapolation of data from patients with IPF because the disease behavior and prognosis of IPF and PPF are comparable (124).”
MethodLeard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Wijsenbeek, M., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 539
Pulmonary fibrosis secondary to COVID-19: a call to arms?
Spagnolo, P., Balestro, E., Aliberti, S., Cocconcelli, E., Biondini, D., Casa, G. D., Sverzellati, N., & Maher, T. M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30222-8 · Cited by 481
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
Maher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A.-M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2503643 · Cited by 205
Self-citation
Metadata
- Authors
- Brown, K. K., Martinez, F. J., Walsh, S. L. F., Thannickal, V. J., Prasse, A., Schlenker-Herceg, R., Goeldner, R.-G., Clerisme-Beaty, E., Tetzlaff, K., Cottin, V., & Wells, A. U.
- Affiliations
- National Jewish Health (US)
- Imperial College London (GB)
- University of Alabama at Birmingham (US)
- Medizinische Hochschule Hannover (DE)
- Boehringer Ingelheim (Germany) (DE)
- Lyon 1 Université (FR)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- Corresponding author
- Brown, Kevin K.
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2020-03-26
- Volume
- 55
- Issue
- 6
- Pages
- 2000085
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC7315005
- OpenAlex
- W3013021754
- Semantic Scholar
- eeb975721a6bad50451a09c9b2ffa308b44a51aa
- Cited by
- 293
- References
- 35
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 46 · 2023: 41 · 2022: 66 · 2021: 62 · 2020: 12
- FWCI
- 25.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft) (submittedVersion)
- Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- progressive fibrosing interstitial lung disease, idiopathic pulmonary fibrosis, natural history (disease), forced vital capacity decline, mortality, ILD progression, INBUILD trial, INPULSIS trials
- MeSH terms
- Aged, Female, Humans, Indoles, Male, Middle Aged, Vital Capacity, Lung Diseases, Interstitial, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.